Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 45Carcinoma, Hepatocellular 13Osteosarcoma 8Neoplasms 8Sarcoma 7Prostatic Neoplasms 7Neoplasm Metastasis 7Colorectal Neoplasms 7Sarcoma, Ewing 6Neuroendocrine Tumors 6Kidney Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Transitional Cell 4Carcinoma, Medullary 4Carcinoma 4Brain Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Thyroid Neoplasms 3Ovarian Neoplasms 3Melanoma 3Endometrial Neoplasms 3Adrenocortical Carcinoma 3Wilms Tumor 2Urogenital Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Stomach Neoplasms 2

Interventions

Nivolumab 4Magnetic Resonance Spectroscopy 4Ipilimumab 3pembrolizumab 2cabozantinib 2aldesleukin 2Specimen Handling 2CTLA-4 Antigen 2Adoptive Transfer 2niraparib 1lenvatinib 1entinostat 1enfortumab vedotin 1dostarlimab 1cemiplimab 1bintrafusp alfa protein, human 1avelumab 1Psychiatric Nursing 1Platinum 1Physical Therapy Modalities 1Palliative Care 1Paclitaxel 1Gemcitabine 1Fluorodeoxyglucose F18 1FAPI-46 1Cisplatin 1CP protocol 1Biopsy 1BAY 1895344 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Penile Neoplasms × cabozantinib × 1 year × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡